Lymphoma
Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma
Who can joinAdults
Age18–99 years
Kind of studyPhase 1: first tests of safety
What it testsA medicine
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Where to go
12 hospitals in India taking patients for this trial.
National Cancer Institute , All India Institute of Medical SciencesJhajjar, HaryanaDirections ↗
Srinivasam Cancer Care Multi Speciality Hospitals India Pvt Ltd. , Bangalore 560072.Bangalore, KarnatakaDirections ↗
Jeevan Amrut Hematology Center, AurangabadAurangabad, MaharashtraDirections ↗
HCG Cancer CentreNagpur, MaharashtraDirections ↗
Sahyadri Hospital Private LimitedPune, MaharashtraDirections ↗
Novo Solitaire CarePune, MaharashtraDirections ↗
Onco Life Cancer, Centre, SataraSatara, MaharashtraDirections ↗
Sunact Cancer Institute Pvt. LtdThane, MaharashtraDirections ↗
Siddharth Gupta Memorial HospitalWardha, MaharashtraDirections ↗
Tata Memorial HospitalParel, MumbaiDirections ↗
AIIMS, BhubaneswarBhubaneswar, OdishaDirections ↗
AIIMS, RishikeshRishikesh, UttarakhandDirections ↗
Registry summary (technical)
A Phase 1, Open Label, Dose Escalation, Multicenter, First-in-Human (FIH) Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR112 in Patients with Relapsed Advanced Lymphoma (ADITI-1)
Sponsor: Aurigene Discovery Technologies Limited
NCT06755450 on ClinicalTrials.gov
Last updated on the registry 13 Jan 2026 · read by us 20 Oct 2026